# AAV Gene Therapy Screening/Observational Protocol (ECLIPSE)

> **NCT04272554** · — · COMPLETED · sponsor: **Spur Therapeutics** · enrollment: 37 (actual)

## Conditions studied

- Hemophilia B
- Blood Coagulation Disorders, Inherited
- Blood Coagulation Disorder
- Haematologic Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04272554
- **Lead sponsor:** Spur Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-14
- **Primary completion:** 2022-10-10
- **Final completion:** 2022-10-10
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04272554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04272554, "AAV Gene Therapy Screening/Observational Protocol (ECLIPSE)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04272554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*